X4 Pharmaceuticals, Inc.
NASDAQ:XFORBiotechnology
+$0.06 today
- Market cap
- $302.26M
- Beta
- 0.37
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.79
Volume 1.12M
Average 0.40M
Income Statement
Follow revenue through to earnings.
Revenue
$35.11M
FY 2025 · Annual
+1273.2% YoYOperating Income
-$86.88M
FY 2025 · Annual
Net Income
-$79.20M
FY 2025 · Annual
Income Statement
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 2.56M | 35.11M |
| Cost of Revenue | 1.89M | 0 | 0 | 797K | 6.26M |
| Gross Profit | (1.89M) | 0 | 0 | 1.76M | 28.86M |
| Gross Margin | — | — | — | 68.8% | 82.2% |
| Research & Development | 48.76M | 61.06M | 72.02M | 81.64M | 72.22M |
| Selling, General & Admin | 24.7M | 27.02M | 35.51M | 61.52M | 43.52M |
| Operating Expenses | 73.46M | 87.57M | 107.52M | 38.16M | 115.74M |
| Depreciation & Amortization | 1.89M | 513K | 419K | 796K | 1.28M |
| EBITDA | (83.15M) | (89.33M) | (94.89M) | (27.58M) | (69.01M) |
| EBITDA Margin | — | — | — | -1078.5% | -196.5% |
| Operating Income | (75.35M) | (87.57M) | (107.52M) | (36.4M) | (86.88M) |
| Operating Margin | — | — | — | -1423.6% | -247.4% |
| Interest Income | 10K | 219K | 4.58M | 5.77M | 4.58M |
| Interest Expense | 3.64M | 3.99M | 5.78M | 8.77M | 8.88M |
| Other Income / Expenses | (13.33M) | (6.27M) | 6.43M | (739K) | 7.73M |
| Income Before Tax | (88.68M) | (93.84M) | (101.09M) | (37.14M) | (79.16M) |
| Pre-Tax Margin | — | — | — | -1452.5% | -225.4% |
| Income Tax Expense | 17K | 28K | 78K | 310K | 41K |
| Net Income | (88.7M) | (93.87M) | (101.17M) | (37.45M) | (79.2M) |
| Net Margin | — | — | — | -1464.6% | -225.6% |
| EPS (Basic) | (119.58) | (45.60) | (17.07) | (5.59) | (1.87) |
| EPS (Diluted) | (119.58) | (45.60) | (17.07) | (5.59) | (1.87) |
| 858.3K | 2.12M | 5.93M | 6.7M | 42.29M | |
| 858.3K | 2.12M | 5.93M | 6.7M | 42.29M |
XFOR Earnings Waterfall · TTM
NASDAQ:XFOR · Revenue to Net Income
Key Ratios
Analysis
$9.0M of revenue converted into -$99.7M of net income for the selected period. Gross margin is 79.2% and net margin is -1168.3%, showing how much revenue survives after costs and taxes. EPS is $-4.54, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Oct 29, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 19, 2026 | |
| 8-K | Current report | Oct 8, 2026 |
How much revenue does XFOR generate?
X4 Pharmaceuticals, Inc. (XFOR) reported $35.11M of revenue in fiscal 2025.
Is XFOR profitable?
X4 Pharmaceuticals, Inc. (XFOR) reported -$79.20M of net income, with a net margin of -225.6%.
Continue the stock analysis
Jump to another research area for this company.